ProMIS Neurosciences Inc PMN

Healthcare Biotechnology

ProMIS Neurosciences Inc. is a clinical-stage biotechnology company. It is focused on generating and developing antibody therapeutics selectively targeting toxic misfolded proteins in neurodegenerative diseases such as Alzheimer’s disease (AD), amyotrophic lateral sclerosis (ALS) and multiple system atrophy (MSA). Its proprietary target discovery engine applies a thermodynamic, computational discovery platform-ProMIS and Collective Coordinates-to predict novel targets known as Disease Specific Epitopes on the molecular surface of misfolded proteins. Using this approach, the Company is developing novel antibody therapeutics for AD, ALS and MSA. Its product candidates are PMN310, PMN267, and PMN442. The PMN310 is a monoclonal antibody designed to treat AD by selectively targeting toxic, misfolded oligomers of amyloid-beta. PMN267 product candidate targeting ALS. PMN442 is a drug candidate being developed for MSA designed to selectively target and protect against pathogenic a-syn species.

NDAQ:PMN - Post by User

ProMIS Neurosciences Inc > Media section/ covid Immunity Passport Page

<< Previous

Bullboard Posts

Next >>

Comment by Gbathaton Oct 30, 2021 5:06pm

137 Views

Post# 34068858

RE:Media section/ covid Immunity Passport Page

let the PR blitz begin! c'mon PMN... toot your horn a bit so you don't have to RS at 60 to 1 to go NASDAQ.

First in North America Test Provides Vital Reassurance of Antibodies Specific to Variants of Concern Including the Delta Variant

https://covidimmunitypassport.com/wp-content/uploads/2021/10/IHG_COVID19-AntibodiesTesting-PressRelease.pdf

<< Previous

Bullboard Posts

Next >>

Advancing flagship Ishkõday Gold Project in Ontario